These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 10707955

  • 1. Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation.
    Oesterreich S, Zhang Q, Hopp T, Fuqua SA, Michaelis M, Zhao HH, Davie JR, Osborne CK, Lee AV.
    Mol Endocrinol; 2000 Mar; 14(3):369-81. PubMed ID: 10707955
    [Abstract] [Full Text] [Related]

  • 2. Novel nuclear matrix protein HET binds to and influences activity of the HSP27 promoter in human breast cancer cells.
    Oesterreich S, Lee AV, Sullivan TM, Samuel SK, Davie JR, Fuqua SA.
    J Cell Biochem; 1997 Nov 01; 67(2):275-86. PubMed ID: 9328833
    [Abstract] [Full Text] [Related]

  • 3. HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer.
    Townson SM, Sullivan T, Zhang Q, Clark GM, Osborne CK, Lee AV, Oesterreich S.
    Clin Cancer Res; 2000 Sep 01; 6(9):3788-96. PubMed ID: 10999774
    [Abstract] [Full Text] [Related]

  • 4. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
    Bindels EM, Lallemand F, Balkenende A, Verwoerd D, Michalides R.
    Oncogene; 2002 Nov 21; 21(53):8158-65. PubMed ID: 12444551
    [Abstract] [Full Text] [Related]

  • 5. Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor.
    Jiang S, Meyer R, Kang K, Osborne CK, Wong J, Oesterreich S.
    Mol Endocrinol; 2006 Feb 21; 20(2):311-20. PubMed ID: 16195251
    [Abstract] [Full Text] [Related]

  • 6. Both N- and C-terminal transactivation functions of DNA-bound ERalpha are blocked by a novel synthetic estrogen ligand.
    Yamamoto Y, Wada O, Takada I, Yogiashi Y, Shibata J, Yanagisawa J, Kitazato K, Kato S.
    Biochem Biophys Res Commun; 2003 Dec 19; 312(3):656-62. PubMed ID: 14680815
    [Abstract] [Full Text] [Related]

  • 7. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
    Montano MM, Ekena K, Krueger KD, Keller AL, Katzenellenbogen BS.
    Mol Endocrinol; 1996 Mar 19; 10(3):230-42. PubMed ID: 8833652
    [Abstract] [Full Text] [Related]

  • 8. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
    Lu M, Miller KD, Gokmen-Polar Y, Jeng MH, Kinch MS.
    Cancer Res; 2003 Jun 15; 63(12):3425-9. PubMed ID: 12810680
    [Abstract] [Full Text] [Related]

  • 9. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V, Gougelet A, Maillard S, Renoir JM.
    Mol Endocrinol; 2003 Oct 15; 17(10):2013-27. PubMed ID: 12855746
    [Abstract] [Full Text] [Related]

  • 10. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.
    Revillion F, Pawlowski V, Lhotellier V, Louchez MM, Peyrat JP.
    Anticancer Res; 2003 Oct 15; 23(2B):1455-60. PubMed ID: 12820409
    [Abstract] [Full Text] [Related]

  • 11. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
    MacGregor Schafer J, Liu H, Bentrem DJ, Zapf JW, Jordan VC.
    Cancer Res; 2000 Sep 15; 60(18):5097-105. PubMed ID: 11016635
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
    Liu X, Pisha E, Tonetti DA, Yao D, Li Y, Yao J, Burdette JE, Bolton JL.
    Chem Res Toxicol; 2003 Jul 15; 16(7):832-7. PubMed ID: 12870885
    [Abstract] [Full Text] [Related]

  • 14. A fusion protein of the estrogen receptor (ER) and nuclear receptor corepressor (NCoR) strongly inhibits estrogen-dependent responses in breast cancer cells.
    Chien PY, Ito M, Park Y, Tagami T, Gehm BD, Jameson JL.
    Mol Endocrinol; 1999 Dec 15; 13(12):2122-36. PubMed ID: 10598586
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
    Fleming FJ, Hill AD, McDermott EW, O'Higgins NJ, Young LS.
    J Clin Endocrinol Metab; 2004 Jan 15; 89(1):375-83. PubMed ID: 14715875
    [Abstract] [Full Text] [Related]

  • 18. Identification of charged residues in an N-terminal portion of the hormone-binding domain of the human estrogen receptor important in transcriptional activity of the receptor.
    Pakdel F, Reese JC, Katzenellenbogen BS.
    Mol Endocrinol; 1993 Nov 15; 7(11):1408-17. PubMed ID: 8114756
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.